Results 221 to 230 of about 373,907 (280)

Multivalent Protein Nanorings for Broad and Potent SARS‐CoV‐2 Neutralization

open access: yesAdvanced Healthcare Materials, EarlyView.
A protein‐only, modular multivalent nanoscaffold displaying 20 anchor points, decorated with two different binders (10 of each), targeting the SARS‐CoV‐2 receptor‐binding domain is presented. The construct self‐assembles into stable, biocompatible, homogeneous nanoparticles, exhibit synergistic binding with fM IC50 values. It also detects spike at 9 ng 
Molood Behbahanipour   +11 more
wiley   +1 more source

Deep learning in fetal, infant, and toddler neuroimaging research. [PDF]

open access: yesDev Cogn Neurosci
Chin JH   +12 more
europepmc   +1 more source

Redefining Therapies for Drug‐Resistant Tuberculosis: Synergistic Effects of Antimicrobial Peptides, Nanotechnology, and Computational Design

open access: yesAdvanced Healthcare Materials, EarlyView.
Antimicrobial peptide (AMP)‐loaded nanocarriers provide a multifunctional strategy to combat drug‐resistant Mycobacterium tuberculosis. By enhancing intracellular delivery, bypassing efflux pumps, and disrupting bacterial membranes, this platform restores phagolysosome fusion and macrophage function.
Christian S. Carnero Canales   +11 more
wiley   +1 more source

Evaluating the Antiviral Efficacy of Encapsulated PKC Inhibitor BIM‐I against influenza A Virus Infection

open access: yesAdvanced Healthcare Materials, EarlyView.
This study explores nanoparticle delivery of the protein kinase C inhibitor bisindolylmaleimide‐I (BIM‐I) to combat influenza A virus infections. Encapsulation in biodegradable PLGA nanoparticles improved safety while maintaining the compound's strong antiviral activity.
Laura Klement   +12 more
wiley   +1 more source

Peptomer Linkers Enable Kinetic Control over Co‐Delivery of Multiple Chemotherapeutics

open access: yesAdvanced Healthcare Materials, EarlyView.
A key challenge in combinatorial chemotherapeutic drug delivery is independent control over release kinetics, especially with drugs of similar size and structure. Here, peptoid substitutions to proteolytically degradable peptides enabled the design of fast and slow‐releasing drug linkers.
Carolyn M. Watkins   +3 more
wiley   +1 more source

Kidney Organoids in Drug Development: Integrating Technological Advances and Standardization for Effective Implementation

open access: yesAdvanced Healthcare Materials, EarlyView.
This review examines how emerging enabling technologies enhance the physiological relevance, scalability, and reproducibility of kidney organoids, while advanced analytical approaches support model validation and deepen mechanistic insight into nephrotoxicity.
Helen Kearney   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy